HCID 58075304, compound → HCID 58075831, compound
Reaction equation
[Cl:1][C:2]1[N:3]=[CH:4][N:5]([C:7]2[CH:12]=[CH:11][C:10]([NH:13][C:14]3[N:15]=[C:16]([NH:32][CH3:33])[C:17]4[CH2:22][CH2:21][CH:20]([C:23]5[CH:28]=[C:27]([F:29])[C:26]([F:30])=[C:25]([F:31])[CH:24]=5)[C:18]=4[N:19]=3)=[CH:9][C:8]=2[O:34][CH3:35])[CH:6]=1>C(=O)=O.CO>[Cl:1][C:2]1[N:3]=[CH:4][N:5]([C:7]2[CH:12]=[CH:11][C:10]([NH:13][C:14]3[N:15]=[C:16]([NH:32][CH3:33])[C:17]4[CH2:22][CH2:21][C@H:20]([C:23]5[CH:28]=[C:27]([F:29])[C:26]([F:30])=[C:25]([F:31])[CH:24]=5)[C:18]=4[N:19]=3)=[CH:9][C:8]=2[O:34][CH3:35])[CH:6]=1Participants
Reactant 1
Product 1
Reagents, catalysts & solvents 2
Procedure
A racemic mixture of N2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N4-methyl-7-(3,4,5-trifluorophenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine (59.8 mg, 0.119 mmol from Example 103) was purified using chiral SFC to afford 19.5 mg of peak A (Example 103A) and 34.8 mg of peak B (Example 103B). SFC Method: Chiralpak OJ-H (4.6×250 mm, 5 μM), 20% methanol (0.1% diethylamine) in CO2, 35° C., flow rate 2.0 mL/min for 16 min, absorbance 268 nm, injection 5 μL of 2 mg/mL solution in methanol (multiple stacked injections), tR (peak A)=9.7 min, tR (peak B) 11.9 min. The absolute stereochemistry of individual enantiomers (Examples 103A and 103B) was not determined LC-MS and 1H NMR analytical data for the separated enantiomers was identical to the racemate (Example 103).
Workup
- customwas purified
- customto afford 19.5 mg of peak A (Example 103A) and 34.8 mg of peak B (Example 103B)
- custom=9.7 min, tR (peak B) 11.9 min
Sources & evidence
- ORD record
- ord-fdabc2a130544c07bcca689638dd0584
- Source dataset
- uspto-grants-2014_01
- Patent number
- US08637525B2
Reaction notes
Loading…